White Guide and Orange Guide Formatting Project - Pfizer

More documents

Recommendations

Info

Referencing Quality Programs During Formulary Discussions Orange Guide – Chapter 14: CGC Tools and Resources Q. If a Managed Care Organization’s formulary decision maker asks me for additional reasons why a Pfizer product should be included on its formulary, may I discuss the quality and variety of our Quality Programs? A. No. A Quality Program may never be offered as a reason for including a Pfizer product on formulary. The quality program may be perceived as an item of value offered to increase prescribing in violation of the anti-kickback laws. Consequently, you must never affirmatively discuss a Quality Program in relation to a formulary decision. If a customer makes an unsolicited inquiry about the availability of Quality Programs, you may address it by: FOR MORE INFORMATION Stating that at the conclusion of your product discussion you can provide information about the Quality Programs that Pfizer makes available to its customers; and Stating that an offer or provision of a Quality Program to the customer is in no way influenced by the customer’s pending formulary decision. Consult the CGC intranet site at http://mmweb2.pfizer.com for information and guidance on CGC Tools and Resources, as well as a listing of available Quality Programs. Questions may be referred to your manager, the Customer Marketing Group, your Regional Attorney or CGC Legal Team. 226 Rev. 09/12 Page 7 of 7
Orange Guide – Chapter 15: Non-Rebate Managed Care Customer Interactions Chapter 15: NON-REBATE MANAGED CARE CUSTOMER INTERACTIONS CONTENTS Non-Rebate Managed Care Customer Interactions Service Agreements .......................................................................................................................................................2 Key Points to Ensure Compliance ......................................................................................................................... 3 Patient Education Programs ......................................................................................................................................... 3 Medication Compliance Programs .............................................................................................................................. 4 Co-Promote Programs ................................................................................................................................................. 4 Collaborations ................................................................................................................................................................ 5 FOR MORE INFORMATION ......................................................................................................................................... 6 227 Rev. 09/12 Page 1 of 6
Page 1 and 2:
Dear Colleagues: Pfizer Inc 235 Eas
Page 3 and 4:
To expand the bookmarks for a chapt
Page 5 and 6:
Orange Guide - Chapter 1: Overview
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Foreign Corrupt Practices Act Orang
Page 17 and 18:
Pfizer’s Corporate Integrity Agre
Page 19 and 20:
Page 21 and 22:
Orange Guide - Chapter 2: Detailing
Page 23 and 24:
Key Points to Ensure Compliance Ora
Page 25 and 26:
Page 27 and 28:
Communicating Formulary Status Mail
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Hospital Protocols Comparative Clai
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Interacting with RMRS Colleagues Or
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Detailing at Journal Club Meetings
Page 49 and 50:
Orange Guide - Chapter 3: Support o
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Medical Education Grants Overview O
Page 57 and 58:
International Grant Activity Orange
Page 59 and 60:
Page 61 and 62:
“Not-for-Profit” Defined Orange
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Information on Pfizer’s External
Page 69 and 70:
Overview Orange Guide - Chapter 3:
Page 71 and 72:
Awards, Scholarships and Fellowship
Page 73 and 74:
Page 75 and 76:
Orange Guide - Chapter 4: Federal E
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Promotional Activities Orange Guide
Page 83 and 84:
Page 85 and 86:
Speaker Program Meals Part-Time VA
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Orange Guide - Chapter 5: Interacti
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Discussing Payer Rebates Medical Ac
Page 117 and 118:
Page 119 and 120:
Orange Guide - Chapter 6: Clinical
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Orange Guide - Chapter 7: P&T Commi
Page 129 and 130:
Page 131 and 132:
Questions From a P&T Committee Memb
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Orange Guide - Chapter 8: Privacy:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Seek Only De-Identified Data Orange
Page 147 and 148:
Consent Forms and Mentorships Orang
Page 149 and 150:
REMEMBER Orange Guide - Chapter 8:
Page 151 and 152:
Proper Use of HCP Prescriber Data O
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Orange Guide - Chapter 9: Speaker P
Page 159 and 160:
Page 161 and 162:
Speaker Selection Scheduling Issues
Page 163 and 164:
Use of Pfizer Approved Speaker Slid
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Providing In-Office Meals to Office
Page 171 and 172:
U.S. HCP Payment Disclosure Policy
Page 173 and 174:
Page 175 and 176:
Closeouts Orange Guide - Chapter 9:
Page 177 and 178:
Page 179 and 180: Physical Separation of Speaker Prog
Page 181 and 182: Chapter 10: STARTERS CONTENTS Start
Page 183 and 184: Key Points to Ensure Compliance Ora
Page 185 and 186: Orange Guide - Chapter 10: Starters
Page 187 and 188: Inclusion of Materials with Starter
Page 191 and 192: Distribution of Starters to Colleag
Page 199 and 200: Orange Guide - Chapter 11: Patient
Page 205 and 206: A special note about Medicare Part
Page 207 and 208: Refer any questions to your team at
Page 209 and 210: Chapter 12: CONTRACTING Introductio
Page 211 and 212: Orange Guide - Chapter 12: Contract
Page 213 and 214: Orange Guide - Chapter 12: Contract
Page 215 and 216: Key Points to Ensure Compliance Ora
Page 217 and 218: Chapter 13: HEALTH SCREENINGS Intro
Page 219 and 220: Orange Guide - Chapter 13: Health S
Page 221 and 222: If organized by Pfizer: Orange Guid
Page 223 and 224: Orange Guide - Chapter 13: Health S
Page 225 and 226: Orange Guide - Chapter 14: CGC Tool
Page 227 and 228: Orange Guide - Chapter 14: CGC Tool
Page 229: Discussing Pfizer Products While Me
Page 233 and 234: Orange Guide - Chapter 15: Non-Reba
Page 235 and 236: Orange Guide - Chapter 15: Non-Reba
Page 237 and 238: Orange Guide - Chapter 16: Consumer
Page 243 and 244: Providing Food to Consumers at a Di
Page 247 and 248: Content of Consumer Slide Decks Att
Page 249 and 250: Adverse Events Orange Guide - Chapt
Page 251 and 252: Orange Guide - Chapter 17: State La
Page 263 and 264: California Orange Guide - Chapter 1
Page 277 and 278: Educational Items Orange Guide - Ch
Page 281 and 282:
Orange Guide - Chapter 17: State La
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Orange Guide - Chapter 18: Meals, E
Page 291 and 292:
Page 293 and 294:
Meals to HCPs Orange Guide - Chapte
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Orange Guide - Chapter 19: Sales Ac
Page 313 and 314:
Pricing Considerations Orange Guide
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321:
show all

White Guide and Orange Guide Formatting Project - Pfizer

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?